$3.09
-2.8%Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Chief Financial Officer
Compensation
$656,045
Chief Operating Officer
Chief Technology Officer
Co-Founder, Chairman & Chief Executive Officer
Compensation
$1,268,030
President, General Counsel, Corporate Secretary & Director
Compensation
$910,878
Vice President of Marketing
During the last 12 months, insiders have purchased $166K worth of SRTS shares, with no selling activity reported.
1.5K
5.00K
0
0.00
+5K
+$5K
2.0K
7.62K
0
0.00
+8K
+$8K
37.0K
149.58K
0
0.00
+150K
+$150K
1.0K
3.37K
0
0.00
+3K
+$3K
Sardano Joseph C
Director, Officer: Chief Executive Officer
$101K
Sachetta Eric
Director
$51K
Sardano Michael
Director, Officer: President And General Counsel
$13K
No selling activity
Strong bullish signal with $166K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Perfect buy/sell ratio. Only buying activity with zero sellingโthe most bullish possible insider signal.
Very strong recent buying momentum. Recent insider purchases significantly outpace sales, suggesting near-term optimism.
3 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Strong confluence of bullish signals: High buy/sell ratio, multiple insiders participating, and recent buying momentum all point to significant insider confidence. This level of coordinated buying often precedes positive developments.
SRTS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | May 29, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | May 27, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | May 31, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 02, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 03, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 30, 2021 | June 04, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 05, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 26, 2019 | June 07, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 26, 2018 | June 08, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 21, 2017 | June 05, 2017 | 2017 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.